Gilead Sciences Inc. / Triangle Pharmaceuticals Inc.
2002 · Acquisition/Merger · $464M · Complete
Announcement Sentiment
92
Strongly positive
Gilead Sciences acquired Triangle Pharmaceuticals for approximately $464 million in cash at $6.00 per share, announced December 4, 2002 via a two-step tender offer that completed in January 2003. The acquisition brought Gilead emtricitabine (later marketed as Emtriva), central to its fixed-dose HIV combination strategy with Viread.